Japanese-Founded Regulatory T-cell Reprogramming Company RegCell Secures $45.8M in Funding and Completes U.S. Headquarters Transition
Funding includes $8.5M from an oversubscribed seed financing with up to $37.3M in non-dilutive investment from The Japan Agency for Medical Research and Development (AMED), underscoring Japan’s commitment to breakthrough therapies Funding will advance RegCell’s first-in-class epigenetic regulatory T-cell reprogramming platform…